Overview

Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This study will determine the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Motesanib diphosphate
Niacinamide